title: Nationwide survey of the development of drug resistance in the pediatric field in 2007 and 2010: drug sensitivity of Haemophilus influenzae in Japan (second report).
abstract: The Drug-Resistant Pathogen Surveillance Group in Pediatric Infectious Disease conducted national surveillance for Haemophilus influenzae in 2007 (phase 3) and 2010 (phase 4), following the previous surveillance conducted from 2000 to 2001 (phase 1) and in 2004 (phase 2). We examined the antimicrobial susceptibility for H. influenzae derived from clinical specimens of pediatric patients collected nationwide from 27 institutions during phases 3 (386 strains) and 4 (484 strains). The frequency of β-lactamase-nonproducing ampicillin (ABPC)-resistant (BLNAR) strains, which rapidly increased from 11.4 % in phase 1 to 43.4 % in phase 2, has gradually decreased from 38.3 % in phase 3 to 37.8 % in phase 4. In contrast, On the other hand, the frequency of β-lactamase-producing strains, which continuously decreased from 8.3 % in phase 1 to 4.4 % in phase 3, has increased to 8.7 % in phase 4. Prevalence of β-lactamase-producing clavulanic acid/amoxicillin-resistant (BLPACR) strains, especially, has increased from 1.6 % in phase 3 to 4.8 % in phase 4. The oral antimicrobial agents with the lowest MIC90 were levofloxacin in both phases, and tosufloxacin in phase 4 (≤0.063 μg/ml), whereas for intravenous use the corresponding agent was tazobactam/piperacillin in both phases (0.125 μg/ml). There was no increase in the MIC90 of most β-lactams between phase 3 and phase 4. In relationship to sex, age, presence of siblings, attendance at a daycare center, siblings' attendance at a daycare center, and prior administration of antimicrobial agents within 1 month, the frequency of β-lactamase-nonproducing ABPC-intermediately resistant (BLNAI) strains + BLNAR strains was high (P = 0.005) in cases with prior administration of antimicrobial agents in phase 3.
authors.affiliation: Division of Infectious Diseases, Chiba Children's Hospital, 579-1 Heta-cho, Midori-ku, Chiba, Chiba, Japan. t.hshn12@pref.chiba.lg.jp
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hoshino
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Sato
authors.forename: Yoshikiyo
authors.initials: Y
authors.lastname: Toyonaga
authors.forename: Hideaki
authors.initials: H
authors.lastname: Hanaki
authors.forename: Keisuke
authors.initials: K
authors.lastname: Sunakawa
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016667:Bacterial Capsules; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D005260:Female; D006192:Haemophilus Infections / Q000453:epidemiology / Q000382:microbiology*; D006193:Haemophilus influenzae / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008297:Male; D008826:Microbial Sensitivity Tests; D062486:Public Health Surveillance
chemical_list: D000900:Anti-Bacterial Agents
references.citation: J Clin Microbiol. 2008 Jan;46(1):361-5
references.pmid: 17977993
references.citation: J Antimicrob Chemother. 2011 Apr;66(4):788-96
references.pmid: 21393206
references.citation: J Clin Microbiol. 1994 Oct;32(10):2382-6
references.pmid: 7814470
references.citation: Antimicrob Agents Chemother. 2010 Jul;54(7):2953-9
references.pmid: 20439616
references.citation: J Infect Chemother. 2013 Feb;19(1):34-41
references.pmid: 22806445
references.citation: Antimicrob Agents Chemother. 2002 Jul;46(7):2208-18
references.pmid: 12069976
references.citation: J Infect Chemother. 2009 Dec;15(6):402-9
references.pmid: 20012732
references.citation: J Antimicrob Chemother. 2006 Jun;57(6):1077-82
references.pmid: 16617062
references.citation: Antimicrob Agents Chemother. 2004 May;48(5):1509-14
references.pmid: 15105098
references.citation: Antimicrob Agents Chemother. 2009 Jan;53(1):267-70
references.pmid: 18955529
references.citation: Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1152-6
references.pmid: 9927709